460
Participants
Start Date
July 4, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
May 31, 2027
HS-20093
HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.
Topotecan
Topotecan will be administered per drug label.
NOT_YET_RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
Shengjing Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Shandong Cancer Hospital, Jinan
NOT_YET_RECRUITING
Shanghai Pulmonary Hospital, Shanghai
NOT_YET_RECRUITING
The First Affiliate Hospital of GUANGZHOU Medical University, Guangzhou
NOT_YET_RECRUITING
Tongji Hospital, Wuhan
Hansoh BioMedical R&D Company
INDUSTRY